RESEARCH REPORT

Lipid lowering drugs prescription and the risk of peripheral neuropathy: an exploratory case-control study using automated databases

Giovanni Corrao¹, Antonella Zambon¹, Lorenza Bertù¹, Edoardo Botteri¹, Olivia Leoni² and Paolo Contiero³

¹ Department of Statistics, University of Milan-Bicocca, Milan, Italy
² Local Health Department of the Province of Varese, Lombardia Region, Italy
³ Cancer Registry of the Province of Varese, Lombardia Region, Italy

Correspondence to:
Correspondence to:
Professor G Corrao
Dipartimento di Statistica, Università degli Studi di Milano-Bicocca, Via Bicocca degli Arcimboldi, 8, Edificio U7, 20126 Milano, Italy; giovanni.corrao{at}unimib.it

Study objective: Although lipid lowering drugs are effective in preventing morbidity and mortality from cardiovascular events, the extent of their adverse effects is not clear. This study explored the association between prescription of lipid lowering drugs and the risk of peripheral neuropathy.

Design: A population based case-control study was carried out by linkage of several automated databases.

Setting: Resident population of a northern Italian Province aged 40 years or more.

Participants: Cases were patients discharged for peripheral neuropathy in 1998–1999. For each case up to 20 controls were randomly selected among those eligible. Altogether 2040 case patients and 36 041 controls were included in the study.

Exposure ascertainment: Prescription drug database was used to assess exposure to lipid lowering drugs at any time in the one year period preceding the index date.

Analysis: Conditional logistic regression model for matched data was used to estimate the risk of peripheral neuropathy associated with exposure to statins, fibrates, and other lipid lowering drugs.

Main results: Weak but significant effects of lipid lowering drugs as a whole (matched odds ratio: 1.27; 95% confidence intervals: 1.05 to 1.55), statins (1.19; 1.00 to 1.40), and fibrates (1.49; 1.03 to 2.17) were observed. Significant linear trends towards increased risk at increased exposure to both statins and fibrates were observed.

Conclusions: The use of both statins and fibrates was associated with the risk of peripheral neuropathy. The primary purpose of this exploratory study is signal generation. This requires further investigations to evaluate the causal role of lipid lowering drugs on the onset of peripheral neuropathy.

Abbreviations: DDD, defined daily dose; ATC, anatomical therapeutic chemical

Keywords: automated databases; lipid lowering drugs; peripheral neuropathy

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

The journal of the increasingly relevant

Carlos Álvarez-Dardet and John R Ashton
J Epidemiol Community Health 2004 58: 965. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Makepeace, A., Davis, W. A., Bruce, D. G., Davis, T. M.E. (2008). Incidence and Determinants of Carpal Tunnel Decompression Surgery in Type 2 Diabetes: The Fremantle Diabetes Study. Diabetes Care 31: 498-500 [Abstract] [Full Text]  
• Corrao, G, Zambon, A, Bertu, L, Botteri, E, Leoni, O, Contiero, P (2005). Lipid lowering drugs prescription and the risk of peripheral neuropathy: an exploratory case-control study using automated databases. Heart 91: 560-560 [Full Text]